Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · IEX Real-Time Price · USD
2.860
-0.040 (-1.38%)
Jul 2, 2024, 4:30 PM EDT - Market closed
Aytu BioPharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Aytu BioPharma stock has a target of 5.00, which predicts an increase of 74.83% from the current stock price of 2.86.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 9, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for Aytu BioPharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '23 | Apr '23 | May '23 | Jun '23 | Jul '23 | Aug '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +74.83% | Aug 9, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +599.30% | May 31, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $220 → $120 | Strong Buy | Maintains | $220 → $120 | +4,095.80% | Jul 21, 2022 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $220 → $100 | Buy | Maintains | $220 → $100 | +3,396.50% | May 17, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $480 → $220 | Strong Buy | Maintains | $480 → $220 | +7,592.31% | Apr 28, 2022 |
Financial Forecast
Revenue This Year
82.95M
from 107.40M
Decreased by -22.76%
Revenue Next Year
79.79M
from 82.95M
Decreased by -3.82%
EPS This Year
-2.54
from -5.11
EPS Next Year
0.79
from -2.54
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 85.4M | 82.1M | 75.2M | 123.6M | 127.4M | 135.8M |
| Avg | 83.0M | 79.8M | 73.0M | 120.1M | 123.7M | 131.9M |
| Low | 79.7M | 76.7M | 70.1M | 115.4M | 118.9M | 126.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -20.5% | -1.0% | -5.8% | 69.3% | 6.1% | 9.7% |
| Avg | -22.8% | -3.8% | -8.5% | 64.4% | 3.1% | 6.6% |
| Low | -25.8% | -7.6% | -12.1% | 58.0% | -1.0% | 2.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -2.61 | 0.81 | 0.39 |
| Avg | -2.54 | 0.79 | 0.38 |
| Low | -2.44 | 0.75 | 0.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | -50.5% |
| Avg | - | - | -51.9% |
| Low | - | - | -53.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.